Answers to frequently asked questions
What is Urge Urinary Incontinence (UUI)?
What is tibial neuromodulation?
What is Revi and how does it treat urgent bladder leaks?
What are the components of the Revi System?
Who are appropriate patients for Revi?
Who should I talk to about Revi to learn more and see if it’s right for me?
Does insurance cover Revi?
What is the Revi procedure like?
Is the Revi procedure safe?
When can I start using Revi?
What does ongoing use of Revi involve?
What does a treatment session feel like?
Has Revi been studied in other patients?
What happens if I need ongoing support after Revi?
How long does the Revi Implant last?
What’s the myRevi app?
How does a small implant in the ankle help you manage your bladder leaking?
Descargas en Español
Could Revi be right for you?
Revi is an innovative therapy for urgent bladder leaks that could provide a key to the symptom relief you have been seeking—unlocking a path forward that you may not have imagined possible.
*Some women (10.6%) had mild to moderate issues, including numbness after the procedure, pain, swelling, skin rash, wound infections, and delayed healing.4
**Of the 130 patients who completed the satisfaction survey.
For further information on the OASIS study and other on-going clinical studies, please visit clinicaltrials.gov (OASIS NCT03596671)
References
1. Heesakkers, J.et al. (2023, April 30). Pivotal Study of a Novel Wirelessly Powered, Patient Tailored Programmed, Tibial Neurostimulator for the Treatment of Patients with Overactive Bladder. AUA 2023.
2. Dorsthorst MJ, Digesu GA, Tailor V, Gore M, van Kerrebroeck PE, van Breda HMK, Elneil S, Heesakkers J. 3-year follow-up of a new implantable tibial nerve stimulator for the treatment of Overactive Bladder Syndrome. Jurol Vol. 204, 545-550, September 202. https://doi.org/10.1097/JU.0000000000001024
3. Revi Surgical Technique Guide August 2023
4. Sutherland, S et. al. OASIS Pivotal Trial to Evaluate the Safety and Efficacy of the Renova iStim System and for the Treatment of Women with OAB. Jurol. 2022; 207(S5):e1043.